Predicting Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach
Clinical Data Scientist Sam Heilbroner, MD, discusses findings from a research abstract accepted at ASCO 2020 that used a machine learning approach to predict adverse events. It is known that ePD-(L)1 therapy is associated with cardiovascular toxicity, including myocarditis. Dr. Heilbroner created a machine learning model to predict cardiac events in PD-(L)1 patients using a large patient sample from the Concerto HealthAI database. Watch this short video on results, conclusions, and implications for industry.